No Prescription |
 |
 | ||
|
Q Pril H Accuretic |
|
| ||
No Prescription » Prescription Drugs 13 » Q Pril H Accuretic Q-Pril-H is indicated in the treatment of hypertension. Antihypertensive combination. Quinapril HCl/hydrochlorothiazide tablets are fixed-combination tablets that combine an angiotensin-converting enzyme (ACE) inhibitor quinapril hydrochloride and a thiazide diuretic hydrochlorothiazide.Quinapril is used in the treatment of high blood pressure. It is combination with a Hydrochlorothiazide . Quinapril is in a family of drugs known as "ACE inhibitors." It works by preventing a chemical in your blood called angiotensin I from converting into a more potent form that increases salt and water retention in your body. Quinapril also enhances blood flow throughout your blood vessels. Along with other drugs Quinapril is also prescribed in the treatment of congestive heart failure.Hydrochlorothiazide is a thiazide diuretic (water pill) that helps prevent your body from absorbing too much salt which can cause fluid retention.Hydrochlorothiazide treats fluid retention (edema) in people with congestive heart failure cirrhosis of the liver or kidney disorders or edema caused by taking steroids or estrogen. This medication is also used to treat high blood pressure (hypertension). Buy Q Pril H Accuretic and other Prescription Drugs 13 products online at Medstore. Buy Online at Medstore - Click Here!
About Q Pril H Accuretic: Product Type: Prescription Drugs 13 Q - Pril H ( Accuretic Acuitel Generic Quinapril & hydrochlorothiazide ) Q - Pril H (Accuretic Acuitel Generic Quinapril & hydrochlorothiazide) Accuretic Acuitel Generic Quinapril & hydrochlorothiazide 10mg - 12.5mg Accuretic Acuitel Generic Quinapril & hydrochlorothiazide Q - Pril H
View more Prescription Drugs 13 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
